RNA mis-splicing in disease

Nature Reviews Genetics

Volumn 17, Issue 1, 2016, Pages 19-32

  Scotti, Marina M ^a   Swanson, Maurice S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA PRECURSOR; ISOPROTEIN; MESSENGER RNA;

DISEASE ASSOCIATION; DISEASES; EXON; GENE MUTATION; GENETIC REGULATION; HUMAN; INDUCED MUTATION; INTRON; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; RNA SEQUENCE; RNA SPLICING; SPLICEOSOME; STRESS; ALTERNATIVE RNA SPLICING; ANIMAL; GENE THERAPY; GENETICS; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; NEOPLASMS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; GENETIC THERAPY; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; NEOPLASMS; PROTEIN ISOFORMS; RNA, MESSENGER; SPLICEOSOMES;

EID: 84951568527     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg.2015.3     Document Type: Review

References (141)

1. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
2. Kim, M. S. et al. A draft map of the human proteome. Nature 509, 575-581 (2014).
3. Wilhelm, M. et al. Mass-spectrometry-based draft of the human proteome. Nature 509, 582-587 (2014).
4. Treutlein, B., Gokce, O., Quake, S. R. and Sudhof, T. C. Cartography of neurexin alternative splicing mapped by single-molecule long-read mRNA sequencing. Proc. Natl Acad. Sci. USA 111, E1291-E1299 (2014).
5. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470-476 (2008).
6. Gerstein, M. B. et al. Comparative analysis of the transcriptome across distant species. Nature 512, 445-448 (2014).
7. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. and Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413-1415 (2008).
8. Singh, R. K. and Cooper, T. A. Pre-mRNA splicing in disease and therapeutics. Trends Mol. Med. 18, 472-482 (2012).
9. Hindorff, L. A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362-9367 (2009).
10. Ashwal-Fluss, R. et al. circRNA biogenesis competes with pre-mRNA splicing. Mol. Cell 56, 55-66 (2014).
11. Barry, G. et al. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing. Mol. Psychiatry 19, 486-494 (2014).
12. Sharp, P. A. Split genes and RNA splicing. Cell 77, 805-815 (1994).
13. Dujardin, G. et al. How slow RNA polymerase II elongation favors alternative exon skipping. Mol. Cell 54, 683-690 (2014).
14. Maquat, L. E. et al. Processing of human β-globin mRNA precursor to mRNA is defective in three patients with β+-thalassemia. Proc. Natl Acad. Sci. USA 77, 4287-4291 (1980).
15. Spritz, R. A. et al. Base substitution in an intervening sequence of a β+-thalassemic human globin gene. Proc. Natl Acad. Sci. USA 78, 2455-2459 (1981).
16. Busslinger, M., Moschonas, N. and Flavell, R. A. β+ thalassemia: aberrant splicing results from a single point mutation in an intron. Cell 27, 289-298 (1981).
17. Takeshima, Y. et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J. Hum. Genet. 55, 379-388 (2010).
18. Fletcher, S. et al. Antisense suppression of donor splice site mutations in the dystrophin gene transcript. Mol. Genet. Genom. Med. 1, 162-173 (2013).
19. Chu, C. S., Trapnell, B. C., Curristin, S., Cutting, G. R. and Crystal, R. G. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat. Genet. 3, 151-156 (1993).
20. Tsui, L. C. and Dorfman, R. The cystic fibrosis gene: a molecular genetic perspective. Cold Spring Harb. Perspect. Med. 3, a009472 (2013).
21. Niblock, M. and Gallo, J. M. Tau alternative splicing in familial and sporadic tauopathies. Biochem. Soc. Trans. 40, 677-680 (2012).
22. Gruenbaum, Y. and Medalia, O. Lamins: the structure and protein complexes. Curr. Opin. Cell Biol. 32, 7-12 (2015).
23. Luo, Y. B., Mastaglia, F. L. and Wilton, S. D. Normal and aberrant splicing of LMNA. J. Med. Genet. 51, 215-223 (2014).
24. Muchir, A. et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum. Mol. Genet. 9, 1453-1459 (2000).
25. Morel, C. F. et al. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2. J. Clin. Endocrinol. Metab. 91, 2689-2695 (2006).
26. Eriksson, M. et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293-298 (2003).
27. De Sandre-Giovannoli, A. et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 300, 2055 (2003).
28. Otomo, J. et al. Electrophysiological and histopathological characteristics of progressive atrioventricular block accompanied by familial dilated cardiomyopathy caused by a novel mutation of lamin A/C gene. J. Cardiovasc. Electrophysiol 16, 137-145 (2005).
29. Liu, M. M. and Zack, D. J. Alternative splicing and retinal degeneration. Clin. Genet. 84, 142-149 (2013).
30. Tanackovic, G. et al. PRPF mutations are associated with generalized defects in spliceosome formation and pre-mRNA splicing in patients with retinitis pigmentosa. Hum. Mol. Genet. 20, 2116-2130 (2011).
31. Linder, B. et al. Identification of a PRPF4 loss of function variant that abrogates U4/U6.U5 tri-snRNP integration and is associated with retinitis pigmentosa. PLoS ONE 9, e111754 (2014).
32. Vaclavik, V., Gaillard, M. C., Tiab, L., Schorderet, D. F. and Munier, F. L. Variable phenotypic expressivity in a Swiss family with autosomal dominant retinitis pigmentosa due to a T494M mutation in the PRPF3 gene. Mol. Vis. 16, 467-475 (2010).
33. Maubaret, C. G. et al. Autosomal dominant retinitis pigmentosa with intrafamilial variability and incomplete penetrance in two families carrying mutations in PRPF8. Invest. Ophthalmol. Vis. Sci. 52, 9304-9309 (2011).
34. Venturini, G., Rose, A. M., Shah, A. Z., Bhattacharya, S. S. and Rivolta, C. CNOT3 is a modifier of PRPF31 mutations in retinitis pigmentosa with incomplete penetrance. PLoS Genet. 8, e1003040 (2012).
35. Comitato, A. et al. Mutations in splicing factor PRPF3, causing retinal degeneration, form detrimental aggregates in photoreceptor cells. Hum. Mol. Genet. 16, 1699-1707 (2007).
36. Mozaffari-Jovin, S. et al. Inhibition of RNA helicase Brr2 by the C terminal tail of the spliceosomal protein Prp8. Science 341, 80-84 (2013).
37. Chen, X. et al. PRPF4 mutations cause autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 23, 2926-2939 (2014).
38. Kevany, B. M. and Palczewski, K. Phagocytosis of retinal rod and cone photoreceptors. Physiology (Bethesda) 25, 8-15 (2010).
39. Farkas, M. H. et al. Mutations in pre-mRNA processing factors 3, 8, and 31 cause dysfunction of the retinal pigment epithelium. Am. J. Pathol. 184, 2641-2652 (2014).
40. David, C. J. and Manley, J. L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24, 2343-2364 (2010).
41. Adler, A. S. et al. An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. Genes Dev. 28, 1068-1084 (2014).
42. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011).
43. Kurtovic-Kozaric, A. et al. PRPF8 defects cause missplicing in myeloid malignancies. Leukemia 29, 126-136 (2014).
44. Yoshida, K. and Ogawa, S. Splicing factor mutations and cancer. Wiley Interdiscip. Rev. RNA 5, 445-459 (2014).
45. Malcovati, L. et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126, 233-241 (2015).
46. Shirai, C. L. et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell 27, 631-643 (2015).
47. Okeyo-Owuor, T. et al. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia 29, 909-917 (2015).
48. Ilagan, J. O. et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 25, 14-26 (2015).
49. Zhang, J. et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc. Natl Acad. Sci. USA 112, E4726-E4734 (2015).
50. Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617-630 (2015).
51. Komeno, Y. et al. SRSF2 is essential for hematopoiesis, and its myelodysplastic syndrome-related mutations dysregulate alternative pre-mRNA splicing. Mol. Cell. Biol. 35, 3071-3082 (2015).
52. Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384-388 (2015).
53. Bonnal, S., Vigevani, L. and Valcarcel, J. The spliceosome as a target of novel antitumour drugs. Nat. Rev. Drug Discov. 11, 847-859 (2012).
54. Abdel-Salam, G. M. et al. A homozygous mutation in RNU4ATAC as a cause of microcephalic osteodysplastic primordial dwarfism type I (MOPD I) with associated pigmentary disorder. Am. J. Med. Genet. A 155, 2885-2896 (2011).
55. Edery, P. et al. Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. Science 332, 240-243 (2011).
56. He, H. et al. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science 332, 238-240 (2011).
57. Jafarifar, F., Dietrich, R. C., Hiznay, J. M. and Padgett, R. A. Biochemical defects in minor spliceosome function in the developmental disorder MOPD I. RNA 20, 1078-1089 (2014).
58. Younis, I. et al. Minor introns are embedded molecular switches regulated by highly unstable U6atac snRNA. eLife 2, e00780 (2013).
59. Licatalosi, D. D. et al. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature 456, 464-469 (2008).
60. Hafner, M. et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141, 129-141 (2010).
61. Konig, J. et al. iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat. Struct. Mol. Biol. 17, 909-915 (2010).
62. Castello, A. et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149, 1393-1406 (2012).
63. Kwon, S. C. et al. The RNA-binding protein repertoire of embryonic stem cells. Nat. Struct. Mol. Biol. 20, 1122-1130 (2013).
64. Moore, M. J. et al. Mapping Argonaute and conventional RNA-binding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. Nat. Protoc. 9, 263-293 (2014).
65. Daneholt, B. Assembly and transport of a premessenger RNP particle. Proc. Natl Acad. Sci. USA 98, 7012-7017 (2001).
66. King, O. D., Gitler, A. D. and Shorter, J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 1462, 61-80 (2012).
67. Kim, H. J. et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467-473 (2013).
68. Kato, M. et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149, 753-767 (2012).
69. Han, T. W. et al. Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell 149, 768-779 (2012).
70. Marangi, G. and Traynor, B. J. Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges. Brain Res. 1607, 75-93 (2014).
71. Renton, A. E., Chio, A. and Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17-23 (2014).
72. Ling, S. C., Polymenidou, M. and Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416-438 (2013).
73. Goodwin, M. and Swanson, M. S. RNA-binding protein misregulation in microsatellite expansion disorders. Adv. Exp. Med. Biol. 825, 353-388 (2014).
74. Prudencio, M. et al. Distinct brain transcriptome profiles in C9orf72 associated and sporadic ALS. Nat. Neurosci. 18, 1175-1182 (2015).
75. Lee, Y. B. et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5, 1178-1186 (2013).
76. Buratti, E. and Baralle, F. E. TDP 43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem. Sci. 37, 237-247 (2012).
77. Arnold, E. S. et al. ALS-linked TDP 43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP 43. Proc. Natl Acad. Sci. USA 110, E736-E745 (2013).
78. Lagier-Tourenne, C. et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP 43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15, 1488-1497 (2012).
79. Nakaya, T., Alexiou, P., Maragkakis, M., Chang, A. and Mourelatos, Z. FUS regulates genes coding for RNA-binding proteins in neurons by binding to their highly conserved introns. RNA 19, 498-509 (2013).
80. Bai, B. et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimers disease. Proc. Natl Acad. Sci. USA 110, 16562-16567 (2013).
81. Li, Y. I., Sanchez-Pulido, L., Haerty, W. and Ponting, C. P. RBFOX and PTBP1 proteins regulate the alternative splicing of micro-exons in human brain transcripts. Genome Res. 25, 1-13 (2015).
82. Sibley, C. R. et al. Recursive splicing in long vertebrate genes. Nature 521, 371-375 (2015).
83. Duff, M. O. et al. Genome-wide identification of zero nucleotide recursive splicing in Drosophila. Nature 521, 376-379 (2015).
84. Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP 43. Nat. Neurosci. 14, 459-468 (2011).
85. Tollervey, J. R. et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP 43. Nat. Neurosci. 14, 452-458 (2011).
86. Ling, J. P., Pletnikova, O., Troncoso, J. C. and Wong, P. C. TDP 43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650-655 (2015).
87. Nelson, S. B. and Valakh, V. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron 87, 684-698 (2015).
88. Irimia, M. et al. A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell 159, 1511-1523 (2014).
89. Gehman, L. T. et al. The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. Nat. Genet. 43, 706-711 (2011).
90. Sebat, J. et al. Strong association of de novo copy number mutations with autism. Science 316, 445-449 (2007).
91. Martin, C. L. et al. Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 869-876 (2007).
92. Weyn-Vanhentenryck, S. M. et al. HITS-CLIP and integrative modeling define the Rbfox splicing-regulatory network linked to brain development and autism. Cell Rep. 6, 1139-1152 (2014).
93. Kole, R., Krainer, A. R. and Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11, 125-140 (2012).
94. Ruegg, U. T. Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr. Opin. Neurol. 26, 577-584 (2013).
95. Kole, R. and Krieg, A. M. Exon skipping therapy for Duchenne muscular dystrophy. Adv. Drug Deliv. Rev. 87, 104-107 (2015).
96. Osorio, F. G. et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci. Transl. Med. 3, 106ra107 (2011).
97. Faravelli, I., Nizzardo, M., Comi, G. P. and Corti, S. Spinal muscular atrophy - recent therapeutic advances for an old challenge. Nat. Rev. Neurol. 11, 351-359 (2015).
98. Li, D. K., Tisdale, S., Lotti, F. and Pellizzoni, L. SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin. Cell Dev. Biol. 32, 22-29 (2014).
99. Cartegni, L., Hastings, M. L., Calarco, J. A., de Stanchina, E. and Krainer, A. R. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am. J. Hum. Genet. 78, 63-77 (2006).
100. Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F. and Krainer, A. R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834-848 (2008).
101. Hua, Y. et al. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev. 29, 288-297 (2015).
102. Lopez Castel, A., Cleary, J. D. and Pearson, C. E. Repeat instability as the basis for human diseases and as a potential target for therapy. Nat. Rev. Mol. Cell Biol. 11, 165-170 (2010).
103. Wang, E. T. et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150, 710-724 (2012).
104. Charizanis, K. et al. Muscleblind-like 2 mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron 75, 437-450 (2012).
105. Wang, E. T. et al. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 25, 858-871 (2015).
106. Wheeler, T. M. et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336-339 (2009).
107. Leger, A. J. et al. Systemic delivery of a peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucleic Acid. Ther. 23, 109-117 (2013).
108. Wheeler, T. M. et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115 (2012).
109. Kendall, G. C. et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci. Transl. Med. 4, 164ra160 (2012).
110. Cherry, J. J. et al. Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol. Med. 5, 1035-1050 (2013).
111. Naryshkin, N. A. et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345, 688-693 (2014).
112. Palacino, J. et al. SMN2 splice modulators enhance U1 pre-mRNA association and rescue SMA mice. Nat. Chem. Biol. 11, 511-517 (2015); erratum 11, 741 (2015).
113. Childs-Disney, J. L. et al. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat. Commun. 4, 2044 (2013).
114. Childs-Disney, J. L. et al. Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity. ACS Chem. Biol. 9, 538-550 (2014).
115. Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A. and Berglund, J. A. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc. Natl Acad. Sci. USA 106, 18551-18556 (2009).
116. Hoskins, J. W. et al. Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Res. 42, 6591-6602 (2014).
117. Jahromi, A. H. et al. A novel CUGexp. MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1. ACS Chem. Biol. 8, 1037-1043 (2013).
118. Niland, C. N., Merry, C. R. and Khalil, A. M. Emerging roles for long non-coding RNAs in cancer and neurological disorders. Front. Genet. 3, 25 (2012).
119. Yang, L., Froberg, J. E. and Lee, J. T. Long noncoding RNAs: fresh perspectives into the RNA world. Trends Biochem. Sci. 39, 35-43 (2014).
120. Tilgner, H. et al. Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co transcriptional in the human genome but inefficient for lncRNAs. Genome Res. 22, 1616-1625 (2012).
121. Gratten, J., Wray, N. R., Keller, M. C. and Visscher, P. M. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat. Neurosci. 17, 782-790 (2014).
122. Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333-338 (2013).
123. Conn, S. J. et al. The RNA binding protein quaking regulates formation of circRNAs. Cell 160, 1125-1134 (2015).
124. Xiong, H. Y. et al. The human splicing code reveals new insights into the genetic determinants of disease. Science 347, 1254806 (2015).
125. Papasaikas, P., Tejedor, J. R., Vigevani, L. and Valcarcel, J. Functional splicing network reveals extensive regulatory potential of the core spliceosomal machinery. Mol. Cell 57, 7-22 (2015).
126. Turunen, J. J., Niemela, E. H., Verma, B. and Frilander, M. J. The significant other: splicing by the minor spliceosome. Wiley Interdiscip. Rev. RNA 4, 61-76 (2013).
127. Braunschweig, U. et al. Widespread intron retention in mammals functionally tunes transcriptomes. Genome Res. 24, 1774-1786 (2014).
128. Ibrahim, E. C. et al. Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia. Hum. Mutat. 28, 41-53 (2007).
129. Muntoni, F., Torelli, S. and Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731-740 (2003).
130. Disset, A. et al. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum. Mol. Genet. 15, 999-1013 (2006).
131. Samaranch, L. et al. PINK1 linked parkinsonism is associated with Lewy body pathology. Brain 133, 1128-1142 (2010).
132. Iovino, M. et al. The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons. Acta Neuropathol. 127, 283-295 (2014).
133. Korvatska, O. et al. Altered splicing of ATP6AP2 causes X linked parkinsonism with spasticity (XPDS). Hum. Mol. Genet. 22, 3259-3268 (2013).
134. Tanackovic, G. et al. A missense mutation in PRPF6 causes impairment of pre-mRNA splicing and autosomal-dominant retinitis pigmentosa. Am. J. Hum. Genet. 88, 643-649 (2011).
135. Cvackova, Z., Mateju, D. and Stanek, D. Retinitis pigmentosa mutations of SNRNP200 enhance cryptic splice-site recognition. Hum. Mutat. 35, 308-317 (2014).
136. Lorson, C. L., Hahnen, E., Androphy, E. J. and Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96, 6307-6311 (1999).
137. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-165 (1995).
138. Sun, S. et al. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1 snRNP. Nat. Commun. 6, 6171 (2015).
139. Guo, W. et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat. Med. 18, 766-773 (2012).
140. Vieira, N. M. et al. A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G). Hum. Mol. Genet. 23, 4103-4110 (2014).
141. Bartoletti-Stella, A. et al. Messenger RNA processing is altered in autosomal dominant leukodystrophy. Hum. Mol. Genet. 24, 2746-2756 (2015).